Does the lipid profile depend on the comorbidity of overweight/obesity and arterial hypertension in patients with type 2 diabetes mellitus?

  • Received 15.06.2021

  • Revised 20.07.2021

  • Accepted 30.08.2021



  • 1,109 Views

  • Retrieved from Volume 3, No. 3, 2021

  • Pages 5-11

Summary. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with diabetes mellitus who have 2–4 times higher risk of CVD compared with non-diabetics. The aim of the study – to analyze the dependence of lipid profile changes on the comorbidity of overweight/obesity and hypertension in patients with type 2 diabetes mellitus. Materials and Methods. For the purpose of retrospective analysis of medical records, 579 patients with type 2 diabetes mellitus (T2DM) were included depending on comorbidity: overweight/obesity and arterial hypertension (AH). Verification of T2DM was performed in accordance with the recommendations of the American Diabetes Association (2019). The diagnosis of stage 1 arterial hypertension (AH) was established according to the ESC/ESH recommendations for AH in 2018. Serum lipid profile was measured using commercially available kits on a Cobas 6000 analyzer (Roche Hitachi, Germany). Results. In patients with comorbid T2DM, obesity and AH, changes in the lipid profile were characterized by significantly higher values of total cholesterol (18.3 %), triglycerides (93.1 %) and residual cholesterol (76.9 %) relative to data with T2DM. Analysis of lipid metabolism in patients with T2DM depending on the presence of hypertension showed a significantly higher concentration of total cholesterol and triglycerides in patients with T2DM with AH, relative to data without AH (p = 0.04). Analysis of lipid metabolism in patients with T2DM depending on the degree of overweight showed that in patients with T2DM with overweight/obesity, lipidogram data are significantly higher than in patients with normal body weight, in particular, the concentration of total cholesterol (15.0 % and 11.8 %), triglycerides (by 43.3 % and 67.2 %), non-cholesterol HDL (by 17.7 % and 15.0 %) and residual cholesterol (by 35.6 % and 52.9 %) respectively. Conclusions. In patients with type 2 diabetes, both hypertension and overweight affect the severity of dyslipidemia

type 2 diabetes mellitus, overweight, obesity, hypertension, comorbidity, lipid profile

https://doi.org/10.11603/bmbr.2706-6290.2021.3.12560

[1] Hevko  U,  Kozak  K,  Krynytska  I,  Marushchak  M. Diagnostic  value  of  a  complete  blood  count  in  type  2 diabetes mellitus and comorbidities. Archives of the Balkan Medical Union. 2020;55(4): 601-7.

[2] Hevko U, Marushchak M. [Genetics of type 2 diabetes mellitus  and  its  combination  with  obesity  and  chronic pancreatitis]. Med i klin khim. 2020;4;103-13.

[3] Hinge  CR,  Ingle  SB,  Adgaonkar  BD.  Body  mass index, blood pressure and lipid profile in type 2 diabetes-review. Int J Cur Res Rev. 2018;10(10): 1-9.

[4] Jayakumari C, Jabbar PK, Soumya S. Lipid profile in  Indian  patients  with  type  2  diabetes:  The  scope  for atherosclerotic  cardiovascular  disease  risk  reduction. Diabetes Spectrum. 2020;33(4): 299-306.

[5] (ADA) American Diabetes Association. Standards of Medical Care in Diabetes – 2019 abridged for primary care providers. Clin Diabetes. 2019;1(37): 11-34.

[6] Williams B, Mancia G, Spiering W. 2018 ESC/ESH Guidelines  for  the  management  of  arterial  hypertension. European Heart Journal. 2018; 39(33): 3021-104.

[7] Body Mass Index: Considerations for Practitioners. URL: https://www.cdc.gov/obesity/downloads/bmiforpactitioners.pdf.

[8] Piepoli  MF,  Hoes  AW,  Agewall  S.  2016  European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of  Cardiology  and  Other  Societies  on  Cardiovascular Disease  Prevention  in  Clinical  Practice  (constituted  by representatives  of  10  societies  and  by  invited  experts). European Heart Journal. 2016;37(29): 2315-81.

[9] Gordon L, Ragoobirsingh D, Morrison EY, Choo-Kang E, McGrowder D, Martorell E. Lipid profile of type 2 diabetic and  hypertensive  patients  in  the  jamaican  population.  J Lab  Physicians.  2010;2(1):  25-30.  DOI:  10.4103/0974-2727.66709. PMID: 21814403; PMCID: PMC3147082.

[10] Lamarche  B,  Després  JP,  Moorjani  S,  Cantin  B, Dagenais GR, Lupien PJ. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study. Atherosclerosis. 1996;119(2): 235-45.

[11] Yarema N, Kotsiuba O, Krytskyy T, Marushchak M,Krynytska  I.  Peculiarities  of  arterial  hypertension  in postmenopausal women with bone mineral density disorders and dyslipidemia. Polish medical journal. 2020;XLVIII(283): 5-9.

[12] Rizzo  M,  Berneis  K.  Lipid  triad  or  atherogenic lipoprotein phenotype: A role in cardiovascular prevention. J Atherosclerosis Thromb. 2005;12(5): 237-9.

[13] Evans  M,  Roberts A,  Davies  S,  Rees A.  Medical lipid-regulating  therapy:  current  evidence,  ongoing  trials and future developments. Drugs. 2004;64: 1181-96.

[14] Dean  BB,  Borenstein  JE,  Henning  JM,  Knight  K, Merz CN. Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk? Am Heart J. 2004;147(6): 939-41.

[15] Steven HM, Seppo L, Tapani R, Kalevi P, Markku L. Mortality from coronary heart disease in subjects with type II diabetes Mellitus and nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4): 229-34.

[16] Preis  SR,  Pencina  MJ,  Hwang  SJ.  Trends  in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart study. Circulation. 2009;120: 212-20.